293 related articles for article (PubMed ID: 30388661)
1. Liquid biopsy: a new diagnostic, predictive and prognostic window in cancers of unknown primary.
El Rassy E; Khaled H; Pavlidis N
Eur J Cancer; 2018 Dec; 105():28-32. PubMed ID: 30388661
[TBL] [Abstract][Full Text] [Related]
2. Cancer of unknown primary site: 20 questions to be answered.
Pavlidis N; Pentheroudakis G
Ann Oncol; 2010 Oct; 21 Suppl 7():vii303-7. PubMed ID: 20943633
[TBL] [Abstract][Full Text] [Related]
3. Molecular characterisation and liquid biomarkers in Carcinoma of Unknown Primary (CUP): taking the 'U' out of 'CUP'.
Conway AM; Mitchell C; Kilgour E; Brady G; Dive C; Cook N
Br J Cancer; 2019 Jan; 120(2):141-153. PubMed ID: 30580378
[TBL] [Abstract][Full Text] [Related]
4. Diagnosis and management of metastatic neoplasms with unknown primary.
Bochtler T; Löffler H; Krämer A
Semin Diagn Pathol; 2018 May; 35(3):199-206. PubMed ID: 29203116
[TBL] [Abstract][Full Text] [Related]
5. Carcinoma of unknown primary with a colon-cancer profile-changing paradigm and emerging definitions.
Varadhachary GR; Raber MN; Matamoros A; Abbruzzese JL
Lancet Oncol; 2008 Jun; 9(6):596-9. PubMed ID: 18510991
[TBL] [Abstract][Full Text] [Related]
6. Molecular assignment of tissue of origin in cancer of unknown primary may not predict response to therapy or outcome: a systematic literature review.
Pentheroudakis G; Greco FA; Pavlidis N
Cancer Treat Rev; 2009 May; 35(3):221-7. PubMed ID: 19046817
[TBL] [Abstract][Full Text] [Related]
7. Cancer of Unknown Primary origin in the genomic era: Elucidating the dark box of cancer.
Economopoulou P; Mountzios G; Pavlidis N; Pentheroudakis G
Cancer Treat Rev; 2015 Jul; 41(7):598-604. PubMed ID: 26033502
[TBL] [Abstract][Full Text] [Related]
8. Integration of genomics and histology revises diagnosis and enables effective therapy of refractory cancer of unknown primary with
Gröschel S; Bommer M; Hutter B; Budczies J; Bonekamp D; Heining C; Horak P; Fröhlich M; Uhrig S; Hübschmann D; Geörg C; Richter D; Pfarr N; Pfütze K; Wolf S; Schirmacher P; Jäger D; von Kalle C; Brors B; Glimm H; Weichert W; Stenzinger A; Fröhling S
Cold Spring Harb Mol Case Stud; 2016 Nov; 2(6):a001180. PubMed ID: 27900363
[TBL] [Abstract][Full Text] [Related]
9. Liquid biopsy: An emerging prognostic and predictive tool in Head and Neck Squamous Cell Carcinoma (HNSCC). Focus on Circulating Tumor Cells (CTCs).
Economopoulou P; Kotsantis I; Kyrodimos E; Lianidou ES; Psyrri A
Oral Oncol; 2017 Nov; 74():83-89. PubMed ID: 29103757
[TBL] [Abstract][Full Text] [Related]
10. Carcinoma of unknown primary (CUP): an update for histopathologists.
Beauchamp K; Moran B; O'Brien T; Brennan D; Crown J; Sheahan K; Cotter MB
Cancer Metastasis Rev; 2023 Dec; 42(4):1189-1200. PubMed ID: 37394540
[TBL] [Abstract][Full Text] [Related]
11. A Review on Cancer of Unknown Primary Origin: The Role of Molecular Biomarkers in the Identification of Unknown Primary Origin.
Yan N; Zhang Y; Guo X; Yuan D; Tian G; Yang J
Methods Mol Biol; 2020; 2204():109-119. PubMed ID: 32710319
[TBL] [Abstract][Full Text] [Related]
12. Liquid biopsy and PCR-free ultrasensitive detection systems in oncology (Review).
Finotti A; Allegretti M; Gasparello J; Giacomini P; Spandidos DA; Spoto G; Gambari R
Int J Oncol; 2018 Oct; 53(4):1395-1434. PubMed ID: 30085333
[TBL] [Abstract][Full Text] [Related]
13. MicroRNA expression profiling with a droplet digital PCR assay enables molecular diagnosis and prognosis of cancers of unknown primary.
Laprovitera N; Riefolo M; Porcellini E; Durante G; Garajova I; Vasuri F; Aigelsreiter A; Dandachi N; Benvenuto G; Agostinis F; Sabbioni S; Berindan Neagoe I; Romualdi C; Ardizzoni A; Trerè D; Pichler M; D'Errico A; Ferracin M
Mol Oncol; 2021 Oct; 15(10):2732-2751. PubMed ID: 34075699
[TBL] [Abstract][Full Text] [Related]
14. [Standard of care of carcinomas on cancer of unknown primary site in 2016].
Benderra MA; Ilié M; Hofman P; Massard C
Bull Cancer; 2016; 103(7-8):697-705. PubMed ID: 27372228
[TBL] [Abstract][Full Text] [Related]
15. Carcinoma of unknown primary (CUP).
Pavlidis N; Fizazi K
Crit Rev Oncol Hematol; 2009 Mar; 69(3):271-8. PubMed ID: 18977667
[TBL] [Abstract][Full Text] [Related]
16. Redefining cancer of unknown primary: Is precision medicine really shifting the paradigm?
Olivier T; Fernandez E; Labidi-Galy I; Dietrich PY; Rodriguez-Bravo V; Baciarello G; Fizazi K; Patrikidou A
Cancer Treat Rev; 2021 Jun; 97():102204. PubMed ID: 33866225
[TBL] [Abstract][Full Text] [Related]
17. Cancers of unknown primary origin: current perspectives and future therapeutic strategies.
Stella GM; Senetta R; Cassenti A; Ronco M; Cassoni P
J Transl Med; 2012 Jan; 10():12. PubMed ID: 22272606
[TBL] [Abstract][Full Text] [Related]
18. Pancreatic cancer: Are "liquid biopsies" ready for prime-time?
Lewis AR; Valle JW; McNamara MG
World J Gastroenterol; 2016 Aug; 22(32):7175-85. PubMed ID: 27621566
[TBL] [Abstract][Full Text] [Related]
19. Liquid biopsy: A new avenue in pathology.
Ghosh RK; Pandey T; Dey P
Cytopathology; 2019 Mar; 30(2):138-143. PubMed ID: 30485558
[TBL] [Abstract][Full Text] [Related]
20. The role of molecular profiling in the diagnosis and management of metastatic undifferentiated cancer of unknown primary
Dermawan JK; Rubin BP
Semin Diagn Pathol; 2021 Nov; 38(6):193-198. PubMed ID: 33309276
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
